Is TVTX Worth Buying in 2026?

Travere Therapeutics, Inc. Common Stock

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-14

Here’s whether Travere Therapeutics, Inc. Common Stock (TVTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+9.83% over 10 days); strong 1-year return of +248.3%; 3-month momentum positive (+85.7%). Currently 1.3% off its 52-week high. Score: +6/7.

Ready to act on this? 📈 Trade on Webull

TVTX is in a confirmed uptrend, trading above both its 50-day ($41.99) and 200-day ($32.89) moving averages. An RSI of 67.4 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +248.3% compares to +22.9% for SPY (beat the market by 225.5%).

$10,000 invested 1 year ago → $34,833 today
vs. S&P 500 (SPY) — same period beat market by 225.5%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($32.89)
Above 50-day MA ($41.99)
RSI(14) neutral zone (30–70) — currently 67.4
Positive return (+248.3%)
Within 10% of period high (−1.3%)
Period Range $52.04
$13.88 $52.72
RSI (14) 67.4
0 · OversoldOverbought · 100

Key Metrics

Price$52.04
Period Return+248.3%
Period High$52.72
Period Low$13.88
Drawdown−1.3%
MA-50$41.99
MA-200$32.89
RSI (14)67.4
Avg Volume (30d)2.4M
vs. SPYbeat by 225.5%
Return Rank#76 of 1246

Trade TVTX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers